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Background: Certain markers have been identified over the last 10 years that facilitate the prediction of a patient’s
prognosis; these markers have been proposed to be useful for risk stratification of lymphoma patients and for the
development of specific therapeutic strategies. In the present study, we assessed the potential prognostic value of
SPRR1A expression in 967 patients with diffuse large B-cell lymphomas.
Methods: All patients were enrolled between 2001 and 2007 (median follow-up, 53.3 months) in the Second
Hospital of Dalian Medical University, First Hospital of China Medical University, and Liaoning Cancer Hospital.
Immunohistochemical analysis was used to evaluate the expression of SPRR1A. Survival was analyzed using
the Kaplan–Meier method. Multivariate analysis was conducted to adjust the effect of SPRR1A expression for
potential, well-known, independent prognostic factors.
Results: Of the 967 patients examined, SPRR1A expression was detected in 305 (31.54%) patients on
immunohistochemical analysis. The 5-year survival rate was significantly lower in patients with SPRR1A expression
than in those without (26.9% vs. 53.2%, P < 0.001). Multivariate analysis identified SPRR1A expression as an independent
predictor of survival in addition to lactate dehydrogenase level, clinical stage, and histologic subtype.
Conclusions: SPRR1A expression may be useful as a prognostic factor for diffuse large B-cell lymphoma.
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Diffuse large B-cell lymphomas (DLBCL) constitute a het-
erogeneous category of aggressive lymphomas [1] that are
diagnosed based on the morphology and immunopheno-
type [2,3], and represent 30–40% of cases of adult non-
Hodgkin’s lymphoma [4]. Although the use of combination
chemotherapy has improved the outcomes of DLBCL,
many patients do not achieve complete remission (CR) and
ultimately relapse. Therefore, it is important to determine
factors that can assist with the identification of patients at a
high risk of recurrent disease [5].
Immunohistochemical tests are routine procedures for
the diagnosis of several malignancies and are considered
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the prediction of a patient’s prognosis. These markers
have been proposed to be useful for risk stratification of
lymphoma patients and for the development of specific
therapeutic strategies. Molecular abnormalities of the cell
death–cell viability balance, as reflected in bcl-2 overexpres-
sion [6-9] or p53 mutation [10,11], have emerged as im-
portant prognostic indicators of DLBCL.
Small proline-rich (SPRR) proteins are characterized
by an unusually high content of proline residues and
were originally identified in cultured keratinocytes as
ultraviolet-inducible genes [12,13]. Several studies have
suggested that SPRRs are related to increased epithelial
proliferation and malignant processes and are markers
for terminal squamous cell differentiation, although they
also function in nonsquamous tissues [14]. Moreover, pri-
mary basal cell carcinomas, squamous cell carcinomas, andLtd. This is an Open Access article distributed under the terms of the Creative
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ably higher level of SPRR1A gene expression [15].
In the present study, we examined 967 specimens ob-
tained from patients with DLBCL to investigate SPRR1A
expression and its prognostic value.
Methods
Patient selection
The present study included patients (n = 2456) with a
pathologically confirmed DLBCL diagnosis who were
treated in the First Hospital of China Medical University,
Fourth Hospital of China Medical University, or Liao-
ning Province Cancer Hospital between January 1, 2001,
and December 31, 2007. At the time of the analysis, 39%
of the slides were available for pathologic review, and
967 patients were considered to have DLBCL (centro-
blastic, immunoblastic, or anaplastic).
Disease dissemination was evaluated before treatment
by physical examination, bone marrow (BM) biopsy, and
computed tomography of the chest and abdomen. Pa-
tients were staged according to the Ann Arbor system.
The number of extranodal sites and larger tumor mass
diameters were also determined. Performance status was
assessed according to the Eastern Cooperative Oncology
Group scale: 0, patient had no symptoms; 1, patient had
symptoms but was ambulatory; 2, patient was bedridden
for less than half of the day; 3, patient was bedridden for
half of the day or longer; and 4, patient was chronically bed-
ridden and required assistance with activities of daily living.
Performance status was then classified as 0–1 (the patient
was ambulatory) or 2–4 (the patient was not ambulatory).
All the patients provided written informed consent, and
the study protocol and the sample collection were approved
by the Ethics Committee of China Medical University.
Assessment of response
The primary endpoint was overall survival. Response
to therapy was evaluated after the initiation of treat-
ment. CR was defined as the disappearance of all
clinical evidence of disease and normalization of all
laboratory values, radiographs, computed tomography
scans, and BM biopsy findings.
Histologic and immunophenotypic study
The histologic diagnosis of DLBCL was independently
determined by 3 pathologists. The diagnosis was based
on morphologic examination of slides from routinely
processed paraffin-embedded samples stained with
hematoxylin-eosin, Giemsa, and Gordon–Sweet stains
and on immunophenotyping results. The immunohisto-
chemistry panel consisted of antibodies against CD20,
CD10, CD3, CD5, BCL2, BCL6, IRF4/MUM1, human
leukocyte antigen (HLA)–DR, and Ki-67.Staining for CD20, CD3, CD10, and HLA-DR was
scored as positive or negative. Each individual case was
unanimously scored as negative or positive by the 3
independent investigators, scored using the 2 matching
scores when the third investigator did not agree, or
recorded as “not evaluable” for a given antigen when
there was no agreement between the investigators.
Staining for CD5, BCL2, IRF4/MUM1, and BCL6 was
scored in a semiquantitative manner, from 1 to 5, indi-
cating the percentage of positive tumor cells: 1, no stain-
ing; 2, 5%–25%; 3, 26%–50%; 4, 51%–75%; and 5, >75%.
For Ki-67 (MIB1), a score of 5 was defined as 76%–90%,
and an additional score of 6 was introduced (>90%).
Whenever individual cores for a given case showed
nonconcordant results, the score of the core with the
highest number of positive cells was recorded.
Patient selection for SPRR1A expression
SPRR1A expression in DLBCL was analyzed when there
were 4 unstained slides available for that case. Only
formalin-fixed specimens were selected, while specimens
fixed in Bouin’s fluid were excluded. To avoid bias related
to treatment, only patients treated with CHOP were
included in the study. Overall, 967 cases were studied for
SPRR1A expression by immunohistochemical analysis.
Immunohistochemical analysis
Thin slices of tumor tissue for all cases were fixed in 4%
formaldehyde solution (pH 7.0) for a duration that did not
exceed 24 hours. The tissues were processed in a routine
manner for paraffin embedding, and 4-μm thick sections
were cut and placed on glass slides coated with 3-
aminopropyl triethoxysilane for immunohistochemical ana-
lysis. The sections were mounted on microscope slides, air
dried, and then fixed in a mixture of 50% acetone and 50%
methanol. The sections were then de-waxed with xylene,
gradually hydrated with gradient alcohol, and washed with
phosphate-buffered saline (PBS). Sections were then incu-
bated for 60 minutes with the primary antibody. After
repeated washing with PBS, the sections were incubated for
30 minutes with the secondary biotinylated antibody
(Multilink Swine anti-goat/mouse/rabbit immunoglobulin;
Dako, Inc.). Thereafter, the avidin-biotin complex (1:1000
dilution; Vector Laboratories, Ltd.) was applied to the
sections for 30–60 minutes at room temperature. The im-
munoreactive products were visualized by catalysis of
3,3′-diaminobenzidine with horseradish peroxidase in the
presence of H2O2, after extensive washing. Sections were
then counterstained in Gill’s Hematoxylin and dehydrated
in ascending grades of methanol, prior to clearing with xy-
lene and mounting under a coverslip.
To identify immunopositive staining for SPRR1A,
SPRR1A expression was first classified semiquantitatively
according to the following criteria: 0, <1% of cells
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discretely expressed SPRR1A; and, 2+, ≥10% of cells
discretely expressed SPRR1A. Samples scored as 1+ or 2+
were considered positive.Statistical analysis
Patient characteristics were compared using the Chi-square
test. Overall survival was analyzed using the Kaplan–Meier
method. The log-rank test was used to analyze survival
differences. Multivariate analysis was conducted to adjust
the effect of SPRR1A expression for potential independent
prognostic factors (age, sex, extranodal sites, performance
status, clinical stage, bulky disease [_____ >10 cm], evolu-
tion, lactate dehydrogenase level, and SPRR1A expression)
using the Cox proportional hazards model with forward
stepwise selection. A P value of <0.05 was consideredTable 1 Characteristics of patients with diffuse large B-cell lym
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IPI, International Prognostic Index; CR, complete remission.statistically significant. All data were analyzed using SPSS
(Version 17.0; SPSS Inc., Chicago, IL, USA).
Results and discussion
SPRR1A expression in diffuse large B-cell lymphomas
The median age of the population was 56 years. Except for
histologic subtype, the clinical characteristics were well
balanced between the 2 groups (SPRR1A − and SPRR1A +
groups) (Table 1). We found that the lymphoma tissue was
positive for anti-SPRR1A staining in 305 (31.54%) cases
(Figure 1).
SPRR1A expression and survival
With a median follow-up of 53.3 months, the 5-year
survival rate was significantly lower in the SPRR1A + group
(26.9% [95% CI, 21.6–32.2%]) than in the SPRR1A − group
(53.2% [95% CI, 48.9–57.5%]; P < 0.001) (Figure 2).phoma according to SPRR1A status





























Figure 1 Expression of SPRR1A in diffuse large B-cell lymphomas by immunohistochemical analysis. (A) Representative case of
large B-cell lymphoma that was positive for SPRR1A expression. (B) Representative case of large B-cell lymphoma that was negative for
SPRR1A expression.
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The hazard ratio for death was 1.792 (95% CI, 1.364–
3.778; P < 0.001) in the SPRR1A + group (Table 2, uni-
variate analysis).
After adjustment for the 11 baseline variables with
the use of Cox regression analysis, the hazard ratio
remained similar (Table 2, multivariate analysis).
Expectedly, the multivariate analyses showed that
clinical stage, lactate dehydrogenase level, and SPRR1AFigure 2 The 5-year survival curve of SPRR1A + and SPRR1A − patientexpression were independent prognostic factors (Table 2,
multivariate analysis).
Predictive value of the expression of SPRR1A for
germinal center B-cell-like/non-germinal center
B-cell-like diagnosis
Considering histologic diagnosis as the gold standard
method for diagnosis, the sensitivity and specificity of
SPRR1A − for the diagnosis of the subtype of germinals with diffuse large B-cell lymphomas.
Table 2 Hazards ratios for death in an intention-to-treat population (n = 967) based on univariable and multivariable
analyses
Univariable analysis Multivariable analysis
HR (95% CI) P* HR (95% CI) P†
Age (years) 0.033 0.421
≤60 y 1 (Ref) 1 (Ref)
>60 y 1.231 (1.017–1.490) 0.033 1.112 (0.762–1.397) 0.421
Sex 0.816 0.736
Women 1 (Ref) 1 (Ref)
Men 1.025 (0.833–1.261) 0.816 1.103 (0.836–1.207) 0.736
Extranodal sites 0.576 0.512
0–1 site 1 (Ref) 1 (Ref)
More than 1 site 1.080 (0.824–1.416) 0.576 1.375 (0.831–1.454) 0.512
Performance status 0.058 0.062
0–1 1 (Ref) 1 (Ref)
2–4 1.755 (0.838–2.146) 0.058 1.172 (0834–1.884) 0.062
Clinical stage 0.000 0.024
I or II 1 (Ref) 1 (Ref)
III or IV 1.742 (1.382–3.666) 0.000 1.217 (1.114–2.371) 0.024
Bulky disease >10 cm 0.221 0.413
No 1 (Ref) 1 (Ref)
Yes 1.177 (0.591–1.529) 0.221 1.124 (0.734–1.349) 0.413
Evolution 0.789 0.442
CR 1 (Ref) 1 (Ref)
No CR 0.901 (0.723–1.122) 0.789 0.834 (0.644–1.176) 0.442
IPI Score 0.007
0–1 1 (Ref)
2 1.236 (1.074–2.537) 0.003
3 1.779 (1.362–2.778) 0.014
4–5 2.343 (1.742–4.621) 0.000
Lactate dehydrogenase 0.011 0.031
Normal 1 (Ref) 1 (Ref)
Elevated 1.921 (1.347–3.312) 0.011 1.383 (1.152–2.511) 0.031
SPRR1A expression 0.000 0.013
Negative 1 (Ref) 1 (Ref)
Positive 1.792 (1.364–3.778) 0.000 1.564 (1.337–2.464) 0.013
HR, hazard ratio; CI, confidence interval; Ref, reference category; IPI, International Prognostic Index; CR, complete remission.
*Derived from tests of HR for prognostic factors in the univariable model.
†Cox-regression analysis, controlling for all of the prognostic factors listed in the table, except IPI Score.
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96.6% (197/204) and 95.8% (203/212), respectively.
The positive predictive value and negative predictive
value of SPRR1A − for GCB DLBCL was 95.6% (197/
206) and 67.7% (203/300), respectively.
In the present study, we determined that SPRR1A
expression is a predictive factor for overall surviv-
al with DLBCL. The classic prognostic factors for
aggressive B-cell lymphomas (i.e., advanced clinicalstage, unfavorable performance status, elevated lactate
dehydrogenase values) and, consequently, the Inter-
national Prognostic Index score were significantly
associated with a poor outcome in these patients. Im-
portantly, the multivariate analyses demonstrated that
the influence of SPRR1A expression on overall survival
was independent of these well-established prognostic
factors. Moreover, SPRR1A can be used to determine
the GCB and non-GCB subtypes of DLBCL.
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SPRR1A was identified as a potential new independent
prognostic factor for DLBCL. These findings may provide
a new molecular framework to identify patients harboring
aggressive B-cell lymphomas.
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